Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection

In personalized medicine, it is often desired to determine if all patients or only a subset of them benefit from a treatment. We consider estimation in two-stage adaptive designs that in stage 1 recruit patients from the full population. In stage 2, patient recruitment is restricted to the part of the population, which, based on stage 1 data, benefits from the experimental treatment. Existing estimators, which adjust for using stage 1 data for selecting the part of the population from which stage 2 patients are recruited, as well as for the confirmatory analysis after stage 2, do not consider time to event patient outcomes. In this work, for time to event data, we have derived a new asymptotically unbiased estimator for the log hazard ratio and a new interval estimator with good coverage probabilities and probabilities that the upper bounds are below the true values. The estimators are appropriate for several selection rules that are based on a single or multiple biomarkers, which can be categorical or continuous.

[1]  Gernot Wassmer,et al.  Designing Issues in Confirmatory Adaptive Population Enrichment Trials , 2015, Journal of biopharmaceutical statistics.

[2]  Werner Brannath,et al.  Shrinkage estimation in two‐stage adaptive designs with midtrial treatment selection , 2013, Statistics in medicine.

[3]  H. Schäfer,et al.  Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections , 2001, Statistics in medicine.

[4]  K. Gabriel,et al.  On closed testing procedures with special reference to ordered analysis of variance , 1976 .

[5]  Jiunn T. Hwang EMPIRICAL BAYES ESTIMATION FOR THE MEANS OF THE SELECTED POPULATIONS , 2016 .

[6]  KyungMann Kim Group Sequential Methods with Applications to Clinical Trials , 2001 .

[7]  Harold B. Sackrowitz,et al.  Two stage conditionally unbiased estimators of the selected mean , 1989 .

[8]  Martin Posch,et al.  Design and estimation in clinical trials with subpopulation selection , 2018, Statistics in medicine.

[9]  Gernot Wassmer,et al.  Planning and Analyzing Adaptive Group Sequential Survival Trials , 2006, Biometrical journal. Biometrische Zeitschrift.

[10]  John Whitehead One-stage and two-stage designs for phase II clinical trials with survival endpoints. , 2014, Statistics in medicine.

[11]  Anastasios A. Tsiatis,et al.  The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time , 1981 .

[12]  Anastasios A. Tsiatis,et al.  Sequential methods for parametric survival models , 1995 .

[13]  Nigel Stallard,et al.  A comparison of methods for constructing confidence intervals after phase II/III clinical trials , 2014, Biometrical journal. Biometrische Zeitschrift.

[14]  Nigel Stallard,et al.  Estimation after subpopulation selection in adaptive seamless trials , 2015, Statistics in medicine.

[15]  M. Kieser,et al.  Point estimation in adaptive enrichment designs , 2017, Statistics in medicine.

[16]  Nigel Stallard,et al.  Point estimation following two‐stage adaptive threshold enrichment clinical trials , 2018, Statistics in medicine.

[17]  Nigel Stallard,et al.  Uniformly minimum variance conditionally unbiased estimation in multi-arm multi-stage clinical trials , 2018 .

[18]  D Magirr,et al.  Simultaneous confidence intervals that are compatible with closed testing in adaptive designs , 2013, Biometrika.

[19]  Werner Brannath,et al.  A new class of powerful and informative simultaneous confidence intervals , 2014, Statistics in medicine.

[20]  W. Lehmacher,et al.  Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.

[21]  Jenny Y. Zhang,et al.  Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study. , 2017, Contemporary clinical trials.

[22]  John Whitehead,et al.  On the bias of maximum likelihood estimation following a sequential test , 1986 .

[23]  Martin Posch,et al.  Nested combination tests with a time‐to‐event endpoint using a short‐term endpoint for design adaptations , 2019, Pharmaceutical statistics.

[24]  P. Bauer,et al.  Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections by H. Schäfer and H.‐H. Müller, Statistics in Medicine 2001; 20: 3741–3751 , 2004, Statistics in medicine.

[25]  Jack Bowden,et al.  Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials , 2008, Biometrical journal. Biometrische Zeitschrift.

[26]  Michael Rosenblum Confidence intervals for the selected population in randomized trials that adapt the population enrolled. , 2013, Biometrical journal. Biometrische Zeitschrift.

[27]  Bart Spiessens,et al.  Adjusted significance levels for subgroup analyses in clinical trials. , 2010, Contemporary clinical trials.

[28]  Nigel Stallard,et al.  Point estimates and confidence regions for sequential trials involving selection , 2005 .

[29]  Xiaoyun Li,et al.  Estimation of treatment effect in two‐stage confirmatory oncology trials of personalized medicines , 2017, Statistics in medicine.

[30]  Daniel J Sargent,et al.  Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. , 2014, Chinese clinical oncology.

[31]  James M. Robins,et al.  Semiparametric Efficiency and its Implication on the Design and Analysis of Group-Sequential Studies , 1997 .

[32]  H Merabet,et al.  The design and analysis of sequential clinical trials , 2013 .

[33]  Jack Bowden,et al.  Accounting for selection and correlation in the analysis of two-stage genome-wide association studies , 2016, Biostatistics.

[34]  N. Simon,et al.  Adaptive enrichment designs for clinical trials. , 2013, Biostatistics.

[35]  Nigel Stallard,et al.  Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials , 2011, Journal of biopharmaceutical statistics.

[36]  Jack Bowden,et al.  Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials , 2013, Biometrical journal. Biometrische Zeitschrift.

[37]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[38]  Tim Friede,et al.  Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial , 2015, Statistics in medicine.

[39]  Nigel Stallard,et al.  Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility , 2013, Statistics in medicine.

[40]  K. Ballman,et al.  Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Julie M Gastier-Foster,et al.  Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Lindsay A. Renfro,et al.  A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer , 2017, Clinical Cancer Research.

[43]  Thomas Jaki,et al.  Estimation in multi‐arm two‐stage trials with treatment selection and time‐to‐event endpoint , 2017, Statistics in medicine.

[44]  Christopher Jennison,et al.  Group Sequential Analysis Incorporating Covariate Information , 1997 .

[45]  Frank Bretz,et al.  Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.

[46]  W. D. Ray 4. Modelling Survival Data in Medical Research , 1995 .

[47]  Jack Bowden,et al.  Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis‐driven selection rules , 2016, Statistics in medicine.

[48]  C. Jennison,et al.  An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.